Novartis doubles down on neurologic gene therapy work with Voyager

No­var­tis has lined up two more neu­ro­log­ic dis­eases in its gene ther­a­py col­lab­o­ra­tion with Voy­ager Ther­a­peu­tics, this time pay­ing about $100 mil­lion up­front to get its hands on cap­sids for Hunt­ing­ton’s dis­ease and spinal mus­cu­lar at­ro­phy. The Tues­day morn­ing deal serves…

#novartis #huntington #unlock